BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 1656030)

  • 1. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; GarcĂ­a-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Ro 24-4736 in antagonizing the platelet and bronchoconstrictor responses to PAF.
    O'Donnell M
    Ann N Y Acad Sci; 1991; 629():416-8. PubMed ID: 1659287
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A; Tahraoui L; Sedivy P; Cavero I
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs.
    Heuer HO
    J Lipid Mediat; 1991; 4(1):39-44. PubMed ID: 1893086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM; Laplace MC; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L; Floch A; Mondot S; Cavero I
    Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
    Dyson MC; Bellan JA; Minkes RK; Beckerman RC; Wegmann MJ; Braquet P; McNamara DB; Kadowitz PJ
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1320-7. PubMed ID: 2175802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.